Spruce Biosciences, Inc.

NASDAQ:SPRB

Biotechnology

Healthcare
$40.49 +5.07%

+$2.47 today

Market cap
$116.37M
Beta
3.20
P/E (TTM)
-1.9
EPS (TTM)
-$27.11
52W Low $7.00High $838.13

Volume 0.05M

Average 0.06M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$33.33M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$43.48M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(42.29M)(46.18M)(47.92M)(53.04M)(38.97M)
Depreciation & Amortization68K74K70K46K21K
Deferred Income Tax00000
Stock-Based Compensation3.96M3.63M4.62M5.35M2.57M
Change in Working Capital1.96M1.13M10.36M(8.57M)(724K)
Accounts Receivables00000
Inventory00000
Accounts Payables(805K)(1.4M)1.91M(2.04M)(352K)
Other Working Capital2.76M2.53M8.45M(6.53M)(372K)
Other Non-Cash Items434K(340K)(404K)249K3.77M
Operating Cash Flow(35.88M)(41.68M)(33.28M)(55.96M)(33.33M)
Capital Expenditures(93K)(8K)(7K)00
Acquisitions (Net)00000
Purchases of Investments(79.08M)(36.8M)(11.88M)00
Sales of Investments060.5M67.67M00
Other Investing Activities00000
Investing Cash Flow(79.17M)23.69M55.78M00
Debt Repayment220K0(1.62M)(1.62M)(2.06M)
Common Stock Issued0(201K)53.62M246K50M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities423K(40K)(2.85M)(246K)(4.53M)
Financing Cash Flow643K(241K)49.14M(1.62M)43.48M
Effect of Forex Changes0187K000
Net Change in Cash(114.4M)(18.05M)71.64M(57.59M)10.15M
Free Cash Flow(35.97M)(41.69M)(33.28M)(55.96M)(33.33M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$39.0M
+ D&A$21.0K
+ Stock-Based Comp$2.6M
+ Deferred Tax$0
- Working Capital-$724.0K
+ Other Non-Cash$3.8M
= Operating Cash Flow-$33.3M
- Capex$0
= Free Cash Flow-$33.3M

Analysis

FY2025 free cash flow is -$33.3M. FCF conversion is 85.5% of net income. Operating cash flow was -$33.3M, with capex of $0. The largest bridge item is Other Non-Cash at $3.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
SC 13GSC 13G filingAug 14, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
SC 13GSC 13G filingAug 14, 2026

Does SPRB generate free cash flow?

Spruce Biosciences, Inc. (SPRB) generated -$33.33M of free cash flow in fiscal 2025.

How much operating cash flow does SPRB produce?

Operating cash flow was -$33.33M, before capital expenditures of $0.00.